PharmacoEconomics & Outcomes News 784, p7 - 12 Aug 2017 AEs have economic impact in patients with NSCLC Adverse events (AEs) associated with treatment of non-small cell lung cancer (NSCLC) including immunotherapies have an economic impact, according to findings of a French study published in ClinicoEconomics and Outcomes Research. Costs of grade 3 and 4 treatment-related AEs reported in ≥1% of patients with NSCLC receiving docetaxel, erlotinib, nivolumab, pembrolizumab, pemetrexed + carboplatin + bevacizumab, ramucirumab + docetaxel, or platinum-based chemotherapies, in phase III clinical trials were evaluated from a French national health insurance perspective. Overall, 24 AEs were identified. Estimated total costs varied from €46 per event to €7742 per year, and were greater than €2000 for 14 AEs. Costs were highest for immunotherapy-related type 1 diabetes mellitus (€7742 per year), and for pneumonitis, anaemia, dehydration and anorexia (€5786, €5752, €5207 and €4349 per event, respectively), and were primarily due to hospitalisation costs. "This study may be of interest for economic evaluations of new interventions in NSCLC," the authors commented. "Among the identified AEs, a majority appeared to have an important economic impact, with a management cost of at least €2,000 mainly driven by hospitalization costs," they concluded. * 2017 euros Chouaid C, et al. Cost analysis of adverse events associated with non-small cell lung cancer management in France. ClinicoEconomics and Outcomes Research : 27 Jul 2017. Available from: URL: https://doi.org/10.2147/ CEOR.S138963 803262559 1173-5503/17/0784-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 12 Aug 2017 No. 784
PharmacoEconomics & Outcomes News – Springer Journals
Published: Aug 12, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera